Flu Vaccine Falls Short as New Virus Strikes

The flu season in the United States is winding down, yet this year’s vaccine has shown lower protection than expected. New data from the Centers for Disease Control and Prevention (CDC) indicates that only about 25% to 30% of adults were kept from needing medical care, while the vaccine cut child hospital visits by roughly 40%. Health officials usually view vaccines as successful when they reach 40% to 60% effectiveness, so this year ranks near the bottom of a twenty‑year trend. The main reason for the shortfall is that the most common virus was not what scientists had predicted. The dominant strain, known as A H3N2 subclade K, spread widely early in winter. The vaccine was designed for a different version of H3N2, creating a mismatch that reduced its impact. Even though this new strain spread more easily, it did not cause noticeably worse illness.Flu cases peaked in December and hit hard in places like New York City, which reported the strongest season in two decades. According to CDC estimates, there have been at least 27 million illnesses, 350, 000 hospitalizations and 22, 000 deaths nationwide. Last year’s figures were higher: 40 million illnesses, 520, 000 hospitalizations and a similar death toll. Among children, at least 101 deaths have occurred this season, with about 85% of those cases involving children who were not fully vaccinated. Vaccination coverage has been moderate. About 46. 5% of adults received a flu shot, slightly above last year’s rate, while roughly 48% of children were vaccinated by late February. These numbers are lower than the 52% rate seen in 2024, and experts say this gap likely worsened the season. Even when a vaccine does not match the circulating virus perfectly, it still helps reduce severe disease. Scientists are already working on next season’s vaccines, and the World Health Organization has recommended that the 2026‑27 formulations include protection against subclade K.